BR112021026575A2 - Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1 - Google Patents

Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1

Info

Publication number
BR112021026575A2
BR112021026575A2 BR112021026575A BR112021026575A BR112021026575A2 BR 112021026575 A2 BR112021026575 A2 BR 112021026575A2 BR 112021026575 A BR112021026575 A BR 112021026575A BR 112021026575 A BR112021026575 A BR 112021026575A BR 112021026575 A2 BR112021026575 A2 BR 112021026575A2
Authority
BR
Brazil
Prior art keywords
glp
glucagon
pharmaceutical compositions
peptides
coagonist
Prior art date
Application number
BR112021026575A
Other languages
English (en)
Inventor
Lucia Gomes Dos Santos Ana
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112021026575A2 publication Critical patent/BR112021026575A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1. a presente invenção fornece formulações para administração parenteral de peptídeos agonistas de glp-1/glucagon, métodos de produção de tais formulações e métodos de tratamento usando tais formulações.
BR112021026575A 2019-07-01 2020-06-30 Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1 BR112021026575A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869263P 2019-07-01 2019-07-01
PCT/EP2020/068411 WO2021001374A1 (en) 2019-07-01 2020-06-30 Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides

Publications (1)

Publication Number Publication Date
BR112021026575A2 true BR112021026575A2 (pt) 2022-04-26

Family

ID=71575348

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026575A BR112021026575A2 (pt) 2019-07-01 2020-06-30 Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1

Country Status (19)

Country Link
US (1) US20230159606A1 (pt)
EP (1) EP3993823A1 (pt)
JP (1) JP2022539200A (pt)
KR (1) KR20220027204A (pt)
CN (1) CN114126639A (pt)
AR (1) AR119324A1 (pt)
AU (1) AU2020299978A1 (pt)
BR (1) BR112021026575A2 (pt)
CA (1) CA3144177A1 (pt)
CL (1) CL2021003497A1 (pt)
CO (1) CO2021017960A2 (pt)
CR (1) CR20220046A (pt)
EA (1) EA202290107A1 (pt)
IL (1) IL289437A (pt)
MA (1) MA56448A (pt)
MX (1) MX2021015930A (pt)
PE (1) PE20220513A1 (pt)
TW (1) TW202116814A (pt)
WO (1) WO2021001374A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
EP3426284B1 (en) 2016-03-10 2024-05-08 MedImmune Limited Glp-1/glucagon agonist for use in the treatment of nonalcoholic steatohepatitis

Also Published As

Publication number Publication date
IL289437A (en) 2022-02-01
CL2021003497A1 (es) 2022-09-30
WO2021001374A1 (en) 2021-01-07
CR20220046A (es) 2022-03-24
AU2020299978A1 (en) 2022-02-24
CO2021017960A2 (es) 2022-01-17
KR20220027204A (ko) 2022-03-07
EA202290107A1 (ru) 2022-03-29
EP3993823A1 (en) 2022-05-11
MX2021015930A (es) 2022-02-03
CN114126639A (zh) 2022-03-01
MA56448A (fr) 2022-05-11
TW202116814A (zh) 2021-05-01
AR119324A1 (es) 2021-12-09
US20230159606A1 (en) 2023-05-25
PE20220513A1 (es) 2022-04-07
JP2022539200A (ja) 2022-09-07
CA3144177A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
MX2018015082A (es) Derivado de fenilpropanamida y metodo de fabricacion y su aplicacion farmaceutica.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MX2021006259A (es) Formulaciones de análogos peptídicos de oxintomodulina.
BR112021026575A2 (pt) Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
IL282842A (en) Medicinal compounds for subcutaneous control
CL2016003271A1 (es) Métodos para tratar infecciones
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
EA202191327A1 (ru) Лекарственные формы терапевтических препаратов от гриппа